CClinicalTrials.gg
Sign In
RecruitingNCT06116604E-BRICUpdated Nov 3, 2023

Early Bowel Resection for Terminal Ileal Crohn's Disease

An observational study in Crohn Disease, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Sheffield Teaching Hospitals NHS Foundation Trust · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
496
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this multicentre mixed -methods study is to understand the patient and clinician perspective on the ideal timing of an operation for Crohn's disease of the terminal ileum (last part of the small bowel). The main questions it aims to answer are:

  • What factors influence patients' and clinicians' preferences with regards to the timing of the first bowel resection for isolated Crohn's disease of the terminal ileum?
  • What are patients' and clinicians' views on 'early' bowel resection (as an alternative to medical therapy) in this context?
  • What are the facilitators and barriers to implementation of early surgery in practice?

Participants will be patients with Crohn's disease of the terminal ileum and healthcare professionals involved in treating inflammatory bowel disease.

Healthcare professionals have previously been asked to participate in an interview to understand their views on the role of surgery for Crohn's disease of the terminal ileum. They will now be invited to participate in a choice exercise to understand how much weight they attribute to various factors and outcomes when choosing between surgery and medication for Crohn's disease of the terminal ileum.

Patients will be asked to participate in:

  1. an interview about their treatment choices
  2. a choice exercise to understand how much weight they attribute to various factors and outcomes when choosing between surgery and medication for Crohn's disease of the terminal ileum
  3. a survey, for patients with a previous ileocaecal resection, assessing their experience of the operation
Read the detailed description

Crohn's disease is localised to the terminal ileum/ileocaecum in a third of patients. Typical medical therapy for ileocaecal Crohn's involves steroids to induce remission, followed by escalation to immunosuppression and/or of biological therapies for refractory disease to maintain remission. Surgery may be considered late in this treatment pathway, when medical therapies have been exhausted or when complications of the disease process arise.

There is a growing body of evidence supporting surgery as a valid option earlier in the treatment pathway. Studies have shown that surgery and medical treatment produce equivalent short term quality of life scores, and that earlier bowel resection is more cost effective. There is also a reduced need for medical therapy and subsequent surgery in patients having an earlier operation compared to those on conventional medical therapy.

Despite the evidence, the concept of "early" surgery has not universally translated into clinical practice. The purpose of this study is to understand why through a mixed-methods study with clinicians and patients. The patient components will be multi-centre (involving up to 10 NHS sites across England and Wales). The aims will be to establish:

  1. the views of clinicians and patients on early primary bowel resection as an alternative to escalation of medical therapy in the context of terminal ileal Crohn's disease
  2. at what point in the treatment pathway surgery is seen as an acceptable option
  3. the facilitators and barriers to implementing early surgery
  4. patient and clinician treatment preferences for terminal ileal Crohn's disease and factors influencing their decision-making

This study consists of the following work packages:

  1. Interviews with healthcare professionals with an interest in inflammatory bowel disease to explore their views on the role of surgery for terminal ileal Crohn's disease - this has already been completed
  2. Interviews with patients with terminal ileal Crohn's disease to explore their views on treatment options including surgery for terminal ileal Crohn's disease
  3. Survey of patients with previous terminal ileal Crohn's disease to assess their decision-regret
  4. Discrete choice experiment with clinicians and patients to understand the weight attributed to different factors and outcomes when choosing between medical treatment and surgery for terminal ileal Crohn's disease
02

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Crohn's disease
  • terminal ileitis
  • ileocaecal Crohn's
  • ileocaecal resection
  • bowel resection
  • shared decision-making
  • qualitative interviews
  • discrete choice experiment
03

In context

Crohn Disease

1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.

This study's planned enrollment of 496 is above the median of 162 across 608 observational studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Sheffield Teaching Hospitals NHS Foundation Trust is the lead sponsor of 207 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with terminal ileal Crohn's disease (current or previous) Healthcare professionals with an interest or expertise in inflammatory bowel disease

Eligibility criteria

  1. Qualitative interviews with patients with terminal ileal (TI) Crohn's disease (CD)

    Inclusion Criteria:

    • Any patient ≥18 years of age, with CD currently or previously affecting the terminal ileum or ileocaecum (with or without involvement of the ascending colon). Where the patient also has concomitant CD affecting other sites, this should be L1-dominant disease (i.e. where treatment is predominantly being required for, or symptoms are predominantly being caused by, disease of the terminal ileum).

    AND

    -The diagnosis of TI CD should have been made in the ten years preceding the start of the study.

    AND

    -The patient should either currently be on steroid-sparing treatment for TI CD, or should have previously been on such treatment (to include enteral nutrition, immunomodulator therapy or biologics), or should have had an ileocolic resection or right hemicolectomy for TI CD.

    Exclusion Criteria:

    • Patients who have never been on any treatment for their TI CD or who have only ever had steroids as treatment (i.e. no other medical or surgical treatment)
    • Unable to communicate in English
  2. Discrete choice experiment Inclusion and exclusion criteria for patient participants are as above in 1.

Eligibility criteria for healthcare professionals are as follows:

  1. Consultant colorectal surgeon with an interest or expertise in IBD, or
  2. Consultant gastroenterologist with an interest or expertise in IBD, or
  3. IBD clinical nurse specialist (IBD CNS), or
  4. any doctor (medical or surgical) undertaking a fellowship in IBD following achievement of their Certificate of Completion of Training, working in an NHS trust in any part of the UK.
  1. Survey of patients with previous ileocaecal resection for CD

Inclusion criteria:

  • Any patient who had their first ileocaecal or ileocolic resection for Crohn's disease of the TI (confirmed using the pathology report for the resected specimen) within 7 years of the launch of the study. Patients who subsequently require a redo ileocolic resection (such as for recurrence in the neo-terminal ileum) during the 7 year study time frame chosen can still be included, as long as their first resection was within the study period.
  • Age 18 years and above
  • Resection with primary anastomosis or with a stoma
  • Elective, emergency and semi-elective operations.

Exclusion criteria:

  1. Ileocaecal or ileocolic resection performed as an emergency operation for the first presentation of Crohn's disease (i.e. in someone not previously diagnosed with Crohn's)
  2. Incidental diagnosis of Crohn's disease as a result of resection performed for an alternative pathology
  3. Resection in the three months preceding the launch of the survey
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
496 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Themes

    Themes generated from analysis of patient interviews

    Time frame: Within 10 years of diagnosis

  2. Trade off preferences for treatments

    Relative importance of attributes from the analysis of the discrete choice experiment

    Time frame: Within 10 years of diagnosis

  3. Patient preference for timing of resection

    Primary outcome for survey of patients with a previous ileocaecal resection

    Time frame: Within 7 years of operation

  4. Decision-regret

    Primary outcome for survey of patients with a previous ileocaecal resection

    Time frame: Within 7 years of operation

Secondary outcomes

  1. Correlation of decision-regret score with pre-operative treatment experiences, Shared-decision making, body image score, selected post-operative outcomes

    Secondary outcome for survey of patients with a previous ileocaecal resection

    Time frame: Within 7 years of operation

07

Study locations

1 of 1 sites recruiting
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield, S5 7AU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116604
Lead sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborators
Sheffield Centre for Health and Related Research, University of Sheffield, Crohn's & Colitis UK
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Sep 7, 2023
Primary completion
Mar 31, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Nov 3, 2023

Study contacts

Debby Dr Hawkins
Contact
debby.hawkins@nhs.net
+44114 2267052
Nilofer Husnoo
Contact
nilofer.husnoo@nhs.net
+44114 2267052
Steven Brown
study chair · Sheffield Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Crohn Disease→

Other studies from this sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Start the discussion